Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic
Adolescent
Antineoplastic Agents
/ therapeutic use
Benzamides
Gene Fusion
Humans
Imatinib Mesylate
/ therapeutic use
Nuclear Pore Complex Proteins
/ genetics
Oncogene Proteins, Fusion
/ genetics
Piperazines
/ pharmacology
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ drug therapy
Protein Kinase Inhibitors
/ pharmacology
Protein Kinases
/ genetics
Pyrimidines
/ therapeutic use
BCR-ABL1-like
acute lymphoblastic leukemia
case report
imatinib
targeted therapy
tyrosine kinase inhibitors
Journal
Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087
Informations de publication
Date de publication:
2022
2022
Historique:
received:
04
05
2022
accepted:
02
09
2022
entrez:
29
9
2022
pubmed:
30
9
2022
medline:
1
10
2022
Statut:
epublish
Résumé
Acute lymphoblastic leukemia (ALL) with recurrent genetic lesions, affecting a series of kinase genes, is associated with unfavorable prognosis, however, it could benefit from treatment with tyrosine kinase inhibitors (TKI).
Identifiants
pubmed: 36172171
doi: 10.3389/pore.2022.1610570
pii: 1610570
pmc: PMC9510372
doi:
Substances chimiques
Antineoplastic Agents
0
Benzamides
0
NUP214 protein, human
0
Nuclear Pore Complex Proteins
0
Oncogene Proteins, Fusion
0
Piperazines
0
Protein Kinase Inhibitors
0
Pyrimidines
0
Imatinib Mesylate
8A1O1M485B
Protein Kinases
EC 2.7.-
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
1610570Informations de copyright
Copyright © 2022 Stukaite-Ruibiene, Norvilas, Dirse, Stankeviciene and Vaitkeviciene.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Leuk Lymphoma. 2019 Nov;60(11):2832-2834
pubmed: 31014138
Exp Ther Med. 2017 Nov;14(5):3979-3984
pubmed: 29067094
Pediatr Blood Cancer. 2020 Jan;67(1):e28019
pubmed: 31556219
J Pediatr Hematol Oncol. 2018 Aug;40(6):e397-e399
pubmed: 29219890
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Leukemia. 2009 Mar;23(3):627-9
pubmed: 18987655
Int J Mol Sci. 2019 Jun 15;20(12):
pubmed: 31208040
N Engl J Med. 2014 Sep 11;371(11):1005-15
pubmed: 25207766
Leukemia. 2005 Sep;19(9):1680-1
pubmed: 16015385
Leukemia. 2014 Feb;28(2):419-22
pubmed: 24048416
Cureus. 2020 Sep 28;12(9):e10696
pubmed: 33133861
Cancer Cell. 2012 Aug 14;22(2):153-66
pubmed: 22897847
Blood. 2017 Nov 9;130(19):2064-2072
pubmed: 28972016
Lancet Oncol. 2009 Feb;10(2):125-34
pubmed: 19138562
Hematology Am Soc Hematol Educ Program. 2011;2011:361-5
pubmed: 22160058
BMC Cancer. 2021 Mar 29;21(1):326
pubmed: 33781217
Eur J Haematol. 2011 May;86(5):361-71
pubmed: 21435002
Haematologica. 2016 Apr;101(4):e133-4
pubmed: 26681761
Blood. 2006 Nov 15;108(10):3556-9
pubmed: 16873673
J Hematol Oncol. 2018 Jun 20;11(1):84
pubmed: 29925402